Reducing cardiovascular morbidity and mortality in the elderly

Blood Pressure, Supplement

Volumn 9, Issue 1, 2000, Pages 40-43

  Trenkwalder, P ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Candesartan cilexetil; Cardiovascular disease; Cognitive function; Dementia; Elderly patients; Hypertension; Study on Cognition and Prognosis in the Elderly

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; CANDESARTAN HEXETIL; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN RECEPTOR; BENZIMIDAZOLE DERIVATIVE; BIPHENYL DERIVATIVE; TETRAZOLE DERIVATIVE;

AGED; ANTIHYPERTENSIVE ACTIVITY; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; COGNITIVE DEFECT; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMENTIA; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; FEMALE; FOLLOW UP; HEART INFARCTION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; STROKE; TREATMENT OUTCOME; ARTICLE; COGNITION; DRUG ANTAGONISM; PATHOPHYSIOLOGY; PROSPECTIVE STUDY;

AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; BIPHENYL COMPOUNDS; COGNITION; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPERTENSION; MALE; MORBIDITY; PROGNOSIS; PROSPECTIVE STUDIES; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTOR, ANGIOTENSIN, TYPE 2; RECEPTORS, ANGIOTENSIN; TETRAZOLES;

EID: 0034577281     PISSN: 08038023     EISSN: None     Source Type: Journal    
DOI: 10.1080/080370500439227     Document Type: Conference Paper

References (22)

1. Twenty-four hour blood pressure profile of different doses of candesartan cilexetil in patients with mild to moderate hypertension
2. Candesartan cilexetil: Safety and tolerability in healthy volunteers and patients with hypertension
3. Candesartan cilexetil, a new generation angiotensin II antagonist, provides dose dependent antihypertensive effect
4. The antihypertensive effect and tolerability of candesartan cilexetil, a new generation angiotensin II antagonist, in comparison with losartan
5. The efficacy of candesartan, an angiotensin II type I receptor antagonist alone or in combination with amlodipine or in combination with amlodipine and hydrochlorothiazide in patients with moderate-to-severe essential hypertension
6. The efficacy and tolerability of candesartan cilexetil in an elderly hypertensive population
7. 1) receptor blockade in hypertensive women: Benefits of candesartan cilexetil versus enalapril and hydrochlorothiazide
8. Effective dose range of candesartan cilexetil for systemic hypertension. Candesartan cilexetil study investigators
9. Protective effects of candesartan cilexetil (TCV116) on stroke, kidney dysfunction and cardiac hypertrophy in stroke-prone spontaneously hypertensive rats
10. Effects of an angiotensin II receptor antagonist TCV-116 on renal haemodynamics in essential hypertension
11. Acute effects of candesartan cilexetil (the new angiotensin II antagonist) on systemic and renal haemodynamics in hypertensive patients
12. Medical research council trial of treatment of hypertension in older adults: Principal results
13. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP)
14. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) trial investigators
15. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension)
16. Blood pressure, stroke and coronary heart disease. I. Effects of prolonged differences in blood pressure - Evidence from nine prospective observational studies corrected for the regression dilution bias
17. Epidemiology and risk of hypertension in the elderly: The Framingham study
18. Treatment of hypertension in the elderly
19. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial
20. A population-based study of dementia in 85-year-olds
21. 15-Year longitudinal study of blood pressure and dementia
22. Study on Cognition and Prognosis in the Elderly (SCOPE)